Render Target: STATIC
Render Timestamp: 2024-11-29T11:07:09.697Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-09-30 01:57:41.692
Product last modified at: 2024-11-22T14:30:09.463Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

GARP/LRRC32 (E2L6B) Rabbit mAb #83565

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 78
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    GARP/LRRC32 (E2L6B) Rabbit mAb recognizes endogenous levels of total GARP/LRRC32 protein. This antibody cross-reacts with an unidentified protein of 32 kDa in some cell extracts.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala292 of human GARP/LRRC32 protein.

    Background

    Leucine-rich repeat containing 32 (LRRC32), also known as glycoprotein A repetitions predominant (GARP), is a key regulator of the TGF-beta family (TGF-β1, TGF-β2, and TGF-β3), and is primarily expressed on the surface of mesenchymal stromal cells, hepatic stellate cells, platelets, and regulatory T cells (Tregs) (1). GARP/LRRC32 enhances the suppressive function of Tregs and decreases the expression of inflammatory cytokines, IL-2, and IFNγ (2,3). GARP/LRRC32 associates via disulfide bonds with the latency-associated peptide (LAP), the regulatory chain of TGF-β, to induce integrin-dependent activation of TGF-β and secretion (1, 3-5), thereby promoting Treg function and homeostasis. As a result, targeting GARP/LRRC32 in combination with other molecules for depleting Tregs or attenuating their suppressive activity represents an opportunity for cancer immunotherapy (6,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.